Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

It's the second "rolling review" of a top coronavirus vaccine candidate in as many days.

Moderna's Coronavirus Vaccine Candidate Advances to Regulatory Review in Canada

Even as major pharma companies face hiccups in their coronavirus vaccine programs, Moderna Inc (NASDAQ: MRNA) is slowly and steadily progressing in its quest to obtain emergency use authorization for its vaccine candidate mRNA-1273 before the year is out.  The Moderna Analyst: Needham analyst Alan Carr has a Buy rating on Moderna with a $94 price target.

Moderna Analyst On Why Coronavirus Vaccine Developer's Stock Is Long-Term Attractive

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19 (mRNA-1273)

Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)

AstraZeneca

BioNTech SE

CureVac B.V

GlaxoSmithKline

Johnson & Johnson

Novavax

Pfizer

Sanofi

There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.

Is the Coronavirus Vaccine Market Oversaturated?

All of the leading COVID-19 vaccine candidates appear to cause some side effects for some recipients. But there's no reason to worry at this point.

Coronavirus Vaccine Side Effects: 3 Key Things You Need to Know

Alexion Pharma

Amgen

Biogen

Gilead Sciences

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data are out for September 30, the most recent settlement date.

Short Sellers Need to Find a Clue on Major Biotechs

Abbott Labs

These stocks could share big news this month, loosening the grip of the coronavirus on our lives.

2 Top Healthcare Stocks to Watch in October

Moderna Doesn't Plan to Enforce Coronavirus Vaccine Patents During Pandemic

Moderna Inc (NASDAQ: MRNA), which could potentially obtain emergency use authorization for its investigational coronavirus vaccine candidate before the year is out, said it will not enforce patents related to its COVID-19 vaccine during the pandemic. What Happened: The Cambridge, Massachusetts-based company said in a Thursday statement that it will not enforce its COVID-19-related patents against others working on vaccines to combat the virus.

Moderna: Coronavirus Vaccine Patents Will Go Unenforced During Pandemic

This would allow other companies developing coronavirus vaccines to use Moderna’s technology.

Covid-19 Vaccine Frontrunner Moderna Won’t Enforce Vaccine Patents During Pandemic

Shares of Moderna Inc. were up 1.2% in premarket trading on Thursday, after a report in The Wall Street Journal said the company would not enforce any of the seven patents it holds for its COVID-19 vaccine candidate during the pandemic. Moderna also told the Journal that it would be willing to license the patents to other organizations when the pandemic ends.

Moderna tells Journal it will not enforce vaccine patents during the pandemic

CAMBRIDGE, Mass.--(BUSINESS WIRE)--DARPA awards Moderna up to $56 million to enable small-scale, rapid mobile manufacturing of nucleic acid vaccines and therapeutics.

DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces updates on respiratory syncytial virus (RSV) vaccine program.

Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program

The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst. Pfizer, Moderna In The Lead: It now appears that Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), along with its German partner BioNTech SE – ADR (NASDAQ: BNTX), have a two month or more advantage over their nearest rivals among coronavirus vaccine developers, SVB Leerink analyst Geoffrey Porges said in a Wednesday note.

Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst

Invesco DWA SmallCap Momentum ETF

Inovio Pharmaceuticals

iShares Russell 2000 Growth ETF

iShares Morningstar Small-Cap Growth ETF

Merck

Vanguard Small-Cap Growth

Vanguard Russell 2000 Growth 

Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.

Here's Why Small-Cap ETFs Are Hitting New Highs

Our indicative theme of Coronavirus Vaccine stocks – which includes a diverse set of U.S. based pharma and biotech stocks that are working on Covid-19 vaccines – is up by about 730% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 4% over the same.

Moderna, Pfizer, Johnson & Johnson: How Are Covid Vaccine Stocks Doing?

NetEase

USA Truck

If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be called earnings acceleration.

4 Stocks With Solid Earnings Acceleration to Watch

That's a slight delay from the companies' best-case scenarios.

Expect Pfizer/BioNTech and Moderna Coronavirus Vaccine Data Readouts in November-December, U.S. Vaccine Program Head Says

In the latest trading session, Moderna (MRNA) closed at $71.04, marking a -1.26% move from the previous day.

Moderna (MRNA) Stock Moves -1.26%: What You Should Know

Pharmaceutical companies developing COVID-19 vaccines should wait two months after late-stage studies conclude to submit an application for an emergency use authorization to the Food and Drug Administration, the regulator said Tuesday.

FDA to require 2-month follow-up period for COVID-19 vaccines before authorization

Pfizer and BioNTech will share the data from their phase 3 clinical trial with the European Medicines Agency as it comes in.

EU Regulators Undertake Rolling Review of Another Coronavirus Vaccine Candidate

Moderna Inc (NASDAQ: MRNA)'s CEO said last week that it will not seek emergency use authorization for its coronavirus vaccine candidate mRNA-1273 before the Nov. 3 U.S. presidential election. Trial Enrollment Hits 94% Of Target:  Moderna's vaccine candidate is in a large-scale Phase 3 trial dubbed COVE with a target enrollment of 30,000 participants.

How Moderna's Slowing COVID-19 Vaccine Enrollment Could Delay Interim Readout

MRNA stock is ready to rally once again, as the company gears up to deliver millions of Covid-19 vaccines in 2021 and help end this crisis. The post Moderna Is Ready To Rally After 2-Month Market Correction appeared first on InvestorPlace.

Moderna Is Ready To Rally After 2-Month Market Correction

Five patients across the two studies apparently experienced chills, fever, and intense headaches.

Report: Moderna and Pfizer Vaccine Trial Participants Report Serious Side Effects

The market may be on a coronavirus rollercoaster, but these stocks continue to see explosive gains.

News for Moderna Stock (MRNA)